There still is no connection between the price of new drugs and the cost of discovering and developing them, even though the pharmaceutical industry has argued for years that such a link was the primary justification for high prices.
Spending on prescription drugs under the Medicare Part D program increased more than 17% in 2014 despite a claims increase of just 3%, and other news
The CMS shared the numbers in its second annual Part D data dump, which comes as rising drug costs have drawn widespread criticism. Under Medicare Part D in 2014, doctors wrote more than 1.4 billion prescriptions, together costing the program and beneficiaries more than $121 billion.
Drugmaker Gilead Sciences saw its earnings fall again amid lower sales of its expensive blockbuster hepatitis C drug Harvoni.
It will soon be easier for Medicaid beneficiaries in Massachusetts to get hepatitis C medications thanks to a new drug rebate program.
Federal health officials have approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
Patently perturbed: Trans-Pacific Partnership trade deal raises fears about drug patent periods, higher costs
Multilateral trade deals—such as the Trans-Pacific Partnership touted by President Barack Obama on his recent trip through Asia—are usually of little concern or consequence to healthcare stakeholders. But the TPP could affect pharmaceutical pricing around the globe.
Institutional investors are pushing for a range of reforms at publicly traded healthcare firms. High on the agenda is easier access to proxy ballots for an alternative slate of board directors.
Biologic drugmaker Gilead Sciences is buying a subsidiary of Nimbus Therapeutics and its experimental medicine for an increasingly prevalent metabolic disorder that causes dangerous fat buildup in the liver.
Everyone is in favor of value-based reimbursement in healthcare, right? If you're still wearing those rose-colored glasses, take a closer look at last week's reaction to Medicare's proposal to test new ways of paying for drugs administered in physician offices and hospital outpatient departments.
There might be another tool in the battle against high drug costs: state consumer protection laws. A potential lawsuit in Massachusetts against drugmaker Gilead over its costly hepatitis C drugs could, if successful, forge a new path for states working to combat the high costs of certain drugs.
Patients with hepatitis C have yet another advanced treatment option, as the Food and Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck.
The Massachusetts attorney general's office is investigating whether the makers of a breakthrough treatment for hepatitis C are violating state law by pricing the drug too high.